Simple liquid biopsy enables targeted therapies in castration-resistant prostate cancer

Share
Print
VIDEO04:34
Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard Scher explains how the formulation of a unique assay, performed by a simple “liquid biopsy” or blood test, is enabling a clearer understanding of the mechanisms underlying resistance to these drugs and will facilitate selection of more targeted therapies in many patients.
Video Details

Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard Scher explains how the formulation of a unique assay, performed by a simple “liquid biopsy” or blood test, is enabling a clearer understanding of the mechanisms underlying resistance to these drugs and will facilitate selection of more targeted therapies in many patients.

Further Reading

http://www.nejm.org/doi/full/10.1056/nejmoa1315815